Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 4/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | ACE | P12821 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4820948 | 0.92 | MAPT (0.46) | ELANEMETAP2PPARAPPARGACE | |
| SCHEMBL4816301 | 0.86 | ELANE (0.58) | ELANEMETAP2PPARAPPARGACE | |
| SCHEMBL8458621 | 0.84 | METAP2 (0.50) | ELANEMETAP2PPARAPPARGACE | |
| SCHEMBL4816519 | 0.80 | ELANE (0.52) | ELANEMETAP2PPARAPPARGACE | |
| SCHEMBL8458627 | 0.79 | METAP2 (0.50) | ELANEMETAP2PPARAPPARGACE | |
| SCHEMBL5930675 | 0.79 | CA12 (0.39) | MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4821873 | 0.78 | ALDH1A1 (0.37) | METAP2ACE | |
| SCHEMBL5930595 | 0.77 | L3MBTL1 (0.39) | RAB9A | |
| SCHEMBL4816414 | 0.77 | ELANE (0.48) | ELANEMETAP2PPARAPPARGACE | |
| SCHEMBL4817666 | 0.76 | PPID (0.50) | METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7347879-B2 | Sulfur-containing secondary para-phenylenediamines dye compositions comprising such para-phenylenediamines, processes, and uses thereof | L'Oreál, S.A. (FR) | 2008-03-25 | — | — | US | claimed |
| US-20060005321-A1 | Sulfur-containing secondary para-phenylenediamines dye compositions comprising such para-phenylenediamines, processes, and uses thereof | L'OREAL S.A. (FR) | 2006-01-12 | — | — | US | claimed |
| US-7347879-B2 | Sulfur-containing secondary para-phenylenediamines dye compositions comprising such para-phenylenediamines, processes, and uses thereof | L'Oreál, S.A. (FR) | 2008-03-25 | — | — | US | disclosed |
| US-7347879-B2 | Sulfur-containing secondary para-phenylenediamines dye compositions comprising such para-phenylenediamines, processes, and uses thereof | L'Oreál, S.A. (FR) | 2008-03-25 | — | — | US | disclosed |
| US-7347879-B2 | Sulfur-containing secondary para-phenylenediamines dye compositions comprising such para-phenylenediamines, processes, and uses thereof | L'Oreál, S.A. (FR) | 2008-03-25 | — | — | US | disclosed |
| US-20060005321-A1 | Sulfur-containing secondary para-phenylenediamines dye compositions comprising such para-phenylenediamines, processes, and uses thereof | L'OREAL S.A. (FR) | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060005321-A1 | Sulfur-containing secondary para-phenylenediamines dye compositions comprising such para-phenylenediamines, processes, and uses thereof | KRT18, CDC73, DSG1 | ELANE 2819/4885METAP2 559/4885PPARA 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.